Literature DB >> 19179551

Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment.

H-G Moon1, W Han, J W Lee, E Ko, E-K Kim, J-H Yu, S Y Kang, W K Moon, N Cho, I-A Park, D-Y Oh, S-W Han, S-A Im, D-Y Noh.   

Abstract

BACKGROUND: Although recent studies suggest high accuracy of breast magnetic resonance imaging (MRI) in predicting residual tumor extent after neo-adjuvant systemic treatment (NST), its use is still controversial. In this study, we aimed to identify predictive factors of MRI accuracy after NST to determine a subgroup of patients in whom the use of MRI provides best additional benefit.
MATERIALS AND METHODS: Clinicopathologic and molecular profiles of breast cancer patients were investigated and their relationships with MRI accuracy were analyzed.
RESULTS: From January 2006 to February 2008, 195 patients received NST and preoperative MRI. In overall, MRI predicted residual tumor extent with higher accuracy than ultrasonography. Triple-negative (TN) tumors showed highest correlation between MRI-measured and pathologic tumor size (r = 0.781) when compared with other subtypes. Multivariate analysis showed age and HER2 expression status as independent factors predicting MRI accuracy. When patients were classified based on their age and HER2 status, relatively older patients (>45) with HER2-negative tumors showed highest MRI accuracy. This finding was further validated using an independent cohort of 63 consecutive patients.
CONCLUSION: Age and HER2 status independently affected MRI accuracy after NST. This observation may guide more tailored approach in using MRI in breast cancer patients undergoing NST.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179551     DOI: 10.1093/annonc/mdn683

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

1.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

Authors:  Jennifer F De Los Santos; Alan Cantor; Keith D Amos; Andres Forero; Mehra Golshan; Janet K Horton; Clifford A Hudis; Nola M Hylton; Kandace McGuire; Funda Meric-Bernstam; Ingrid M Meszoely; Rita Nanda; E Shelley Hwang
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

2.  Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Authors:  Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang
Journal:  Oncologist       Date:  2017-03-17

3.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

4.  Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Christine E McLaren; Wen-Pin Chen; Peter T Fwu; David J B Hsiang; Karen T Lane; John A Butler; Min-Ying Su
Journal:  J Surg Oncol       Date:  2013-10-28       Impact factor: 3.454

5.  Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?

Authors:  Zijing Zhang; Wei Zhang; Yiting Jin; Hongying Wang; Fei Gu; Jian Zhou; Zhengyin Lao; Zude Xu; Feng Tang; Liping Zou; Weijun Tang; Rong Lu; Qiang Zou
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

6.  Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging.

Authors:  A Fangberget; L B Nilsen; K H Hole; M M Holmen; O Engebraaten; B Naume; H-J Smith; D R Olsen; T Seierstad
Journal:  Eur Radiol       Date:  2010-12-03       Impact factor: 5.315

7.  Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer.

Authors:  Hyeong-Gon Moon; Jae Kyo Yi; Hee Sung Kim; Hea Young Lee; Kyung-Min Lee; Minju Yi; Sookyung Ahn; Hee-Chul Shin; Ji-hyun Ju; Incheol Shin; Wonshik Han; Dong-Young Noh
Journal:  BMC Cancer       Date:  2012-12-10       Impact factor: 4.430

8.  The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review.

Authors:  M B I Lobbes; R Prevos; M Smidt; V C G Tjan-Heijnen; M van Goethem; R Schipper; R G Beets-Tan; J E Wildberger
Journal:  Insights Imaging       Date:  2013-01-29

Review 9.  Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Jeon-Hor Chen; Min-Ying Su
Journal:  Biomed Res Int       Date:  2013-06-05       Impact factor: 3.411

10.  Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis.

Authors:  Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.